NCT05225064 is a NA clinical trial of Incentives to be vaccinated in Vaccination Refusal, sponsored by Yale University.

Who is sponsoring NCT05225064?

NCT05225064 is sponsored by Yale University.

What drugs are being tested in NCT05225064?

Interventions in NCT05225064: Incentives to be vaccinated, Mask, Encouragement to wear a mask, Vaccination made more convenient, Social mobilization campaign to be vaccinated.

What condition does NCT05225064 study?

NCT05225064 studies Vaccination Refusal.

Is NCT05225064 still recruiting?

NCT05225064 is currently completed. Last updated 22 June 2022.

Last reviewed 2022-06-22 · How we verify

NCT05225064

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Increasing COVID-19 Vaccine Uptake in Developing Countries (Bihar)

Completed NA Last updated 22 June 2022

What this trial tests

NA trial testing Incentives to be vaccinated in Vaccination Refusal in 114,512 participants. Completed in 27 April 2022.

Timeline

19 January 2022

Primary endpoint
27 April 2022

27 April 2022

Quick facts

Lead sponsor	Yale University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	114,512
Start date	19 January 2022
Primary completion	27 April 2022
Estimated completion	27 April 2022
Sites	1 location across India

Drugs / interventions tested

Incentives to be vaccinated
Mask
Encouragement to wear a mask
Vaccination made more convenient
Social mobilization campaign to be vaccinated

Conditions studied

Vaccination Refusal — all drugs for Vaccination Refusal →

Sponsor

Yale University

Who can join

15 and older, any sex, with Vaccination Refusal. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Working with governments in Bihar, India, we will evaluate a number of mechanisms to increase vaccine uptake. These include household vaccination visits instead of community vaccination clinic.monetary and non-monetary incentives, and concurrent mask promotion. This ClinicalTrials entry contains results only for the study in Bihar.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Vaccination Refusal

Currently open trials in the same condition.

NCT04779827 — Improving Health Equity for COVID-19 Vaccination for At-risk Populations Using Online Social Networks · NA · active not recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05225064 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 22 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05225064.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing